Treatment-free Remission After Achieving Sustained MR4.5 on Nilotinib (ENESTop)

NCT01698905 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

163

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Myeloid Leukemia

Interventions

DRUG: nilotinib

Sponsor

Novartis Pharmaceuticals